http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Sl Ki, Kim,Hyungjin Park,Eun Ji Lim,Seong kyun Lee,Jung Min Han,Jong-Hui Shin,Eun-Sol Lee,Soowon Cho 한국응용곤충학회 2008 한국응용곤충학회 학술대회논문집 Vol.2008 No.05
With the help of KLTER/ME and KLPS in Woraksan, we have surveyed monthly diversity and seasonal prevalence of Macrolepidoptera in Wol-ak-san [Mt.], Jecheon for the period of five months from May to September since 2005. In 2007, to reduce variation, we chose two monitoring points from each of three representative vegetations in the area: Quercus mongolica-, Quercus variabilis- and Pinus densiflora-formations, abbreviated as QM, QV and PD, respectively, and collected exclusively larger moths with bucket-type of light traps for quantified survey. As a result, 1) QM and QV showed the much higher species diversity than PD; 2) in number of individuals collected, QM was the highest, almost twice that of QV, and nearly 8 times that of PD; 3) in Noctuidae and Geometridae collected, QM was the highest, while in Pyralidae and Arctiidae collected, QV was the highest; 4) June was the highest in species diversity, then July was a deep drop, probably due to a storm occurred in July; 5) the number of individuals collected may not be a good indicator as one species may be dominant too much in number of individuals: e.g., Idaea biselata collected in QM in June was over 200, changing the average number of individuals per species to 6.92, which more than twice that of all other sites per month.
Prospects for dengue vaccines for travelers
Sl-Ki Lim,이용석,남궁석,Jacqueline K Lim,윤인규 대한백신학회 2016 Clinical and Experimental Vaccine Research Vol.5 No.2
Travel-acquired dengue cases have been increasing as the overall global dengue burden has expanded. In Korea, imported dengue cases have been reported since 2000 when it first became a notifiable disease. During the first four months of 2016, three times more dengue cases were reported in Korea than during the same period the previous year. A safe and efficacious vaccine for travelers would be beneficial to prevent dengue disease in individual travelers and potentially decrease the risk of virus spread to non-endemic areas. Here, we summarize the characteristics of dengue vaccines for travelers and review dengue vaccines currently licensed or in clinical development.
Sl Ki Kim,Eun-Sol Lee,Seong Kyun Lee,Jung Min Han,Soowon Cho 한국응용곤충학회 2008 한국응용곤충학회 학술대회논문집 Vol.2008 No.10
A recent study on Neuroptera brought us an attention to a newly found group, Coniopterygidae, dustywings. As we reported for the first time this year, this family has not been taxonomically reported in South Korea while it has been reported in North Korea before. In fact, this is known to be found in Japan and China, which means this probably have been around us for a long time. However, we found there was one species of which the name was once mentioned in a paper in 1978. It was reported by Kim, H.S. et al. in 1978 in a study of citrus red mite and its natural enemies (Kim et al., 1978). Although the spelling of the species was wrong even as a synonym, the species was found to be a natural enemy of citrus red mite, Panonychus citri in Jeju-do. We here report this taxonomically undescribed species for the first time in South Korea. The species is superficially similar to white flies but, unlike white flies, it is on our side as a natural enemy.
서영석(YS Seo),송찬호(CH Song),임상혁(SH Lim),박선국(SK Park),송근일(KI Song),남상륜(SL Nam) 대한산부인과학회 1997 Obstetrics & Gynecology Science Vol.40 No.6
Traditionally, preeclamptic women who meet established criteria for severe disease are delivered expeditiously. Although delivery is always appropriate thrapy for the mother, it may not be for the fetus remote from term. The purpose of this investigation was to evaluate the differences of pregnancy and neonatal outcome of severe preeclampsia and normal pregnancy, especially before 34 weeks gestational age, and to determine whether aggressive or expectant management of severe preeclampsia before 34 weeks is more beneficial to maternal and fetal outcome. A hundred and twenty consecutive pregnancies complicated by severe preeclampsia and a hundred and twenty normal pregnancies were stuided. The results were as follows: 1. The incidence of severe preeclampsia was 3.9%(130 of 3328). The 26~30 year old age group was most common, 43%(52 patients). 2. In case of study between severe preeclamptic patients and normal pregnant patient, there was no differences regarding gestational age at delivery, birth weight, cesarean section rate, incidence of RDS, perinatal death. The 1min/5 min Apgar scores of severe preeclampsia is significantly lower than control group(6/7 vs 7/8, p<0.05). Neonates with SGA (small for gestational age) were found in 29% neonates of patients with severe preeclampsia, which is significantly higher than normal pregnancy group(6%, p<0.05). 3. There was no significant difference between expectant(n=10) and aggressive(n=21) management group less than 34 weeks gestation regarding the gestational age of admission and delivery, blood pressure, proteinuria, serum creatinine, hemoglobin, hematocrit, pletelets, liver enzymes, and LDH. Only the prolongation of gestational age in the expectant management group is significantly higher than in the aggressive management group(7 vs 2 days, p<0.05). 4. The neonatal and pregnancy outcome of expectant(n=10) and aggressive management group(n=15) were as follow: The birth weight in the expectant management group is lower than in the aggressive management group(1316.7±668.8g vs 1576.2±428.7 g, p< 0. 05). The incidence of SGA in the expectant management group is higher than in the aggressive management gorup(50% vs 27%, p=not significant). There was no significant difference between expectant and aggressive management group regarding the 1 min/ 5 min Apgar score, the cesarean section rate, and the frequency of respiratory distress syndrome, cerebral hemorrhage, renal failure, sepsis, DIC of neonates.
Lee, Jung-Seok,Mogasale, Vittal,Lim, Jacqueline K.,Ly, Sowath,Lee, Kang Sung,Sorn, Sopheak,Andia, Esther,Carabali, Mabel,Namkung, Suk,Lim, Sl-Ki,Ridde, Valé,ry,Njenga, Sammy M.,Yaro, Seydou,Yoon Public Library of Science 2019 PLoS neglected tropical diseases Vol.13 No.2
<▼1><P><B>Background</B></P><P>Dengue fever is a rapidly growing public health problem in many parts of the tropics and sub-tropics in the world. While there are existing studies on the economic burden of dengue fever in some of dengue-endemic countries, cost components are often not standardized, making cross-country comparisons challenging. Furthermore, no such studies have been available in Africa.</P><P><B>Methods/Principal findings</B></P><P>A patient-specific survey questionnaire was developed and applied in Burkina Faso, Kenya, and Cambodia in a standardized format. Multiple interviews were carried out in order to capture the entire cost incurred during the period of dengue illness. Both private (patient’s out-of-pocket) and public (non-private) expenditure were accessed to understand how the economic burden of dengue is distributed between private and non-private payers.</P><P>A substantial number of dengue-confirmed patients were identified in all three countries: 414 in Burkina Faso, 149 in Kenya, and 254 in Cambodia. The average cost of illness for dengue fever was $26 (95% CI $23-$29) and $134 (95% CI $119-$152) per inpatient in Burkina Faso and Cambodia, respectively. In the case of outpatients, the average economic burden per episode was $13 (95% CI $23-$29) in Burkina Faso and $23 (95% CI $19-$28) in Kenya. Compared to Cambodia, public contributions were trivial in Burkina Faso and Kenya, reflecting that a majority of medical costs had to be directly borne by patients in the two countries.</P><P><B>Conclusions/Significance</B></P><P>The cost of illness for dengue fever is significant in the three countries. In particular, the current study sheds light on the potential economic burden of the disease in Burkina Faso and Kenya where existing evidence is sparse in the context of dengue fever, and underscores the need to achieve Universal Health Coverage. Given the availability of the current (CYD-TDV) and second-generation dengue vaccines in the near future, our study outcomes can be used to guide decision makers in setting health policy priorities.</P></▼1><▼2><P><B>Author summary</B></P><P>Dengue fever is a major public health concern in many parts of South-East Asia and South America. In addition to countries where dengue has been highly prevalent for many years, there is a growing concern on the undocumented burden of dengue in Africa. Following the successful execution of the first-round economic burden study in Vietnam, Thailand, and Colombia by the Dengue Vaccine Initiative, the second-round economic burden study was implemented in Burkina Faso, Kenya and Cambodia using the same standardized methodology. In particular, the second-round study targeted GAVI eligible countries for future vaccine introductions and included two African countries where the burden of dengue was relatively unknown. Our study outcomes show that the economic burden of dengue fever is significant in all three countries. The dengue vaccination era began in 2016 with the first dengue vaccine (CYD-TDV) although its public use should be carefully determined due to the safety concerns related to the vaccine. Considering that there are other second-generation dengue vaccines in development, the current study outcomes provide an important step to estimate the economic benefits of vaccination in the three countries.</P></▼2>